Eurobio Scientific Team
Comunicati stampa
Current year
2025
Eurobio Scientific increases its footprint in Italy
March 12, 2025
Calendrier de publications financières 2025
Janvier 15, 2025 (FR)
Prior years
2024
Opening of the public purchase offer until November 27
October 24, 2024 (FR)
Results for the first half of 2024
September 24, 2024
Suspension of the liquidity contract
August 1, 2024 (FR)
Publication of the 2023 financial annual report
April 26, 2024 (FR)
2023 Annuel revenue at 130,1 MEUR
January 30, 2024
Capital reduction through cancellation of treasury shares-2024
January 9, 2024
2023
Catherine Courboillet to join the Board as an Independant Member
November 7, 2023
Availability of the 2023 half-yearly financial report
October 30, 2023 (FR)
GenDx reduces organ matching time to 3 hours
October 17, 2023
Acquisition of D.I.D. in Italy
June 13, 2023
First IVDR CE marking of PCR tests
May 23, 2023
Publication of the 2022 annual financial report
April 28, 2023 (FR)
Wietse Mulder, CEO of GenDx, holds a 2% stake in Eurobio Scientific
February 14, 2023
2022 annual turnover of €152.5M
January 23, 2023
H2 2022 report on the liquidity contract
January 5, 2023 (FR)
2022
Half-year financial report available
October 27, 2022 (FR)
H1 2022 Results: continued growth of non-COVID activity
October 11, 2022
Half-year report on liquidity contract
July 11, 2022 (FR)
Eurobio Scientific's annual shareholders' meeting
June 14, 2022 (FR)
Availability of the 2021 annual financial report
April 28, 2022 (FR)
Maintaining high level results in 2021
April 6, 2022
Strategic partnership with NextStage AM
February 7, 2022
2021 TURNOVER : Exceptional level of €184.1million
January 24, 2022
Eurobio Scientific confirms its eligibility to the pea-pme system
January 10, 2022 (FR)
